CLU has been reported to have tumor suppressor activity in prostate, lung, and oral cancers, and low expression of CLU is associated with worse prognosis and genetic instability (Panico et al., 2009; Rizzi and Bettuzzi, 2009; Kadam et al., 2021). This evidence concerns the gene CLU and neoplasm.